Greg Zante, Chief Financial Officer at Viking Therapeutics, Inc. (VKTX), sold 133,512 shares at $75.49 ($10.0M) on 2024-05-03, disclosed to the SEC on 2024-05-03.
Scheduled sale ($10.0M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $73.49 | 3,101 | $228K | 2.3% |
| 2 | $73.49 | 3,101 | $228K | 2.3% |
| 3 | $74.44 | 45,570 | $3.4M | 34.0% |
| 4 | $74.44 | 45,570 | $3.4M | 34.0% |
| 5 | $75.49 | 17,238 | $1.3M | 13.0% |
| 6 | $75.49 | 17,238 |
| $1.3M |
| 13.0% |
| 7 | $76.07 | 847 | $64K | 0.6% |
| 8 | $76.07 | 847 | $64K | 0.6% |
| Total | $74.69 avg | 133,512 | $10.0M | 100% |
| Filing → |
| VKTX | SELL | 2025-10-28 | $216K | — | Filing → |
| VKTX | SELL | 2025-07-03 | $237K | — | Filing → |
| VKTX | SELL | 2025-01-06 | $4.1M | — | Filing → |